Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 1
2001 1
2009 1
2010 1
2012 1
2013 3
2014 5
2015 7
2016 8
2017 6
2018 11
2019 9
2020 12
2021 9
2022 6
2023 5
2024 4
2025 6
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Results by year

Filters applied: . Clear all
Page 1
Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period.
Warren RB, Lebwohl M, Thaçi D, Gooderham M, Pinter A, Paul C, Gisondi P, Szilagyi B, White K, Deherder D, Staelens F, Lambert J, Strober B. Warren RB, et al. Among authors: szilagyi b. Br J Dermatol. 2025 Jun 20;193(1):44-55. doi: 10.1093/bjd/ljaf032. Br J Dermatol. 2025. PMID: 39862230 Clinical Trial.
Role of sepsis modulated circulating microRNAs.
Szilágyi B, Fejes Z, Pócsi M, Kappelmayer J, Nagy B Jr. Szilágyi B, et al. EJIFCC. 2019 Jun 24;30(2):128-145. eCollection 2019 Jun. EJIFCC. 2019. PMID: 31263389 Free PMC article. Review.
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials.
Lebwohl M, Merola JF, Strober B, Armstrong A, Yoshizaki A, Gisondi P, Szilagyi B, Peterson L, de Cuyper D, Cross N, Davies O, Gottlieb AB. Lebwohl M, et al. Among authors: szilagyi b. J Am Acad Dermatol. 2024 Aug;91(2):281-289. doi: 10.1016/j.jaad.2024.03.041. Epub 2024 Apr 6. J Am Acad Dermatol. 2024. PMID: 38588819 Free article. Clinical Trial.
Mathematical Modeling.
Szilágyi B. Szilágyi B. Adv Biochem Eng Biotechnol. 2026 Mar 13. doi: 10.1007/10_2025_296. Online ahead of print. Adv Biochem Eng Biotechnol. 2026. PMID: 41820682
Discovery of selective fragment-sized immunoproteasome inhibitors.
Kollár L, Gobec M, Szilágyi B, Proj M, Knez D, Ábrányi-Balogh P, Petri L, Imre T, Bajusz D, Ferenczy GG, Gobec S, Keserű GM, Sosič I. Kollár L, et al. Among authors: szilagyi b. Eur J Med Chem. 2021 Jul 5;219:113455. doi: 10.1016/j.ejmech.2021.113455. Epub 2021 Apr 20. Eur J Med Chem. 2021. PMID: 33894528
Decadentate Acyclic Chelators for Lanthanum Radiopharmaceuticals.
Freire-García A, Babi Araujo Y, Wuest M, Szilágyi B, Madarasi E, Valencia L, Argibay-Otero S, Rodríguez-Rodríguez A, Esteban-Gómez D, Tircsó G, Wuest F, Platas-Iglesias C. Freire-García A, et al. Among authors: szilagyi b. J Med Chem. 2025 Aug 28;68(16):17823-17839. doi: 10.1021/acs.jmedchem.5c01558. Epub 2025 Aug 19. J Med Chem. 2025. PMID: 40830910 Free PMC article.
96 results